Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 6Ovarian Neoplasms 4Breast Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma 2Adenocarcinoma 2Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Mesothelioma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1

Interventions

pembrolizumab 20Paclitaxel 13Fluorouracil 13Docetaxel 13Radiotherapy 12Oxaliplatin 11Cisplatin 11Capecitabine 8Carboplatin 7Leucovorin 6Cetuximab 5Nivolumab 4Albumin-Bound Paclitaxel 4atezolizumab 3Trastuzumab 3Ramucirumab 3Irinotecan 3Interleukin-2 3Injections 3Epirubicin 3Drug Therapy 3Dexamethasone 3130-nm albumin-bound paclitaxel 3tremelimumab 2tisotumab vedotin 2regorafenib 2patritumab deruxtecan 2oblimersen 2nedaplatin 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esophageal Neoplasms × poly ICLC × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡